Bausch Health Companies Inc. · TSX:BHC
Bausch Health Companies — Shareholder Meeting (April 2018)
19 slides from Bausch Health Companies's shareholder meeting presentation, Apr 30, 2018
Slide 1: 2018 Annual Meeting of Shareholders
2018 Annual Meeting of Shareholders April 30, 2018 Laval, Quebec
Slide 2: Forward-Looking Statements
Forward-Looking Statements Forward-Looking Statements cause actual results and events to differ materially from those This presentation contains forward-looking information and described in these forward-looking statements. These risks and statements, within the meaning of applicable securities laws
Slide 3: Non-GAAP Information
Non-GAAP Information To supplement the financial measures prepared in accordance with limitations as analytical tools and should not be considered in U.S. generally accepted accounting principles (GAAP), the Company isolation. They should be considered as a supplement to, not a uses certain non-GAAP
Slide 4: Introductions – Board of Directors
Introductions – Board of Directors Joseph C. Papa Richard U. De Schutter D. Robert Hale Dr. Argeris (Jerry) N. Sarah B. Kavanagh Chairman Karabelas John A. Paulson Robert N. Power Russel C. Robertson Thomas W. Ross, Sr. Amy B. Wechsler, M.D. 4
Slide 5: Remarks from Chairman & CEO Joseph C. Papa
Remarks from Chairman & CEO Joseph C. Papa 2018 Annual Meeting of Shareholders April 30, 2018 5
Slide 6: Impact on the World Today
Impact on the World Today Every day up to 150 million people around the world use a Valeant product. 6
Slide 7: Recognition and Achievements Since Last Year
Recognition and Achievements Since Last Year Bausch + Lomb Ranked in the Top 2018 Recipient of Two for CEO, CFO SDHB Pheo-Para Waterford Named the American Red and IR for Mid-Cap Coalition Corporate Overall Winner of the Cross William W. Pharma on Leadership Award 2017 Medtech Augustine Award Recipi
Slide 8: Our Mission and Values
Our Mission and Values OUR VISION TO BE YOUR TRUSTED HEALTH CARE PARTNER Quality Customer Health Care Innovation Efficiency People Focused Outcomes MISSION To Improve People’s Lives With Our Health Care Products 8
Slide 9: Tangible Progress Toward Transformation
Tangible Progress Toward Transformation O U R M I S S I O N : Improve people’s lives with our health care products. STABILIZE TURNAROUND TRANSFORM 2016 2017-2018 2018+ Resolving legacy issues and de-risking the balance sheet Investing in core franchises with attractive growth Launching new produc
Slide 10: Delivering on Commitments in 2017: Executing on Core Businesses
Delivering on Commitments in 2017 Executing on Core Businesses • ~75% of total revenue generated from the B+L/International segment and the Salix business • 6% B+L/International segment organic revenue growth1,2 in FY17 versus FY16 and generated mid- single digit organic growth 1,2 during each of th
Slide 11: Delivering on Commitments in 2017: Growing Pipeline and Launching New Products
Delivering on Commitments in 2017 Growing Pipeline and Launching New Products • Launched more than 100 new products globally in 2017 Launched AQUALOX® contact lenses in Japan BRYHALI™ 1 (IDP-122) Introduced Biotrue® ONEday for Astigmatism Thermage FLX™ daily disposable contact lenses in 20 countri
Slide 12: Delivering on Commitments in 2017
Delivering on Commitments in 2017 Reduced Debt and Extended Maturities • As of Feb. 28, 2018, reduced total debt by more than $6.7 billion since the end of the first quarter of 2016 • As of Feb. 28, 2018, reduced debt repayment requirements through 2020 by more than $10.8 billion since Dec. 31, 2016
Slide 13: Full-Year Guidance Targets Throughout 2017
Full-Year Guidance Targets Throughout 2017 FY 2017 FY 2017 FY 2017 FY 2017 FY 2017 Guidance Guidance Guidance Guidance Reported as of February 2017 as of May 2017 as of August 2017 as of November 2017 Results $8.90B to $8.90B to $8.70B to $8.65B to Revenue $8.72B $9.10B $9.10B $8.90B $8.80B Adj. $3.
Slide 14: Excited About 2018 and Beyond
Excited About 2018 and Beyond XIFAXAN® TRx +6% in First Nine Weeks of RELISTOR® TRx +46% in First Nine Weeks of 2018 vs. First Nine Weeks of 20171 2018 vs. First Nine Weeks of 20171 18,500 1,600 18,000 1,500 1,400 17,500 17,270 1,311 1,300 17,000 Christmas 1,200 16,500 Thanksgiving 15,803 1,100 16,0
Slide 15: Excited About 2018 and Beyond
Excited About 2018 and Beyond MIGRANAL®/MIGRANAL® AG Monthly TRx +38% in Jan. 2018 vs. Jan. 20171,2,3 4,800 4,300 3,974 3,800 3,300 2,882 2,800 2,300 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2016 2017 2018 15 1. NPA Audit from February 2012 to January 2018. 2. NPA Weekly Audit from February 1
Slide 16: Core Business Catalysts: 2018 and Beyond
Core Business Catalysts: 2018 and Beyond Bausch + Lomb Ortho Dermatologics Salix VYZULTA™ Launch (now) Increased dermatology sales force PLENVU®1 - PDUFA date May by >25% in Jan. 2018 13, 2018 Stellaris Elite™ Launch (now) Launching SILIQ™ XIFAXAN ® Next Generation LUMIFY™ Launch (2Q18
Slide 17: Significant Seven
Significant Seven New Product Approvals Expected to Drive Long-Term Growth1 <$100M in annualized revenues >$1B in expected annualized today peak total revenues over the next five years 1 RELISTOR® (methylnatrexone bromide) BRYHALI™ 1 (IDP-122) SiHy Daily1 VYZULTA™ (latanoprostene bunod ophthalmic so
Slide 18: Management Commitments and Expected Targets
Management Commitments and Expected Targets Commitment Action Plan and Expected Targets Ortho Dermatologics Double Revenue Over the Next 5 Years Generate Annualized Revenues of >$1B Over Next Significant Seven 5 Years Prioritize the use of cash flow to reduce debt Address Debt Continue to ad
Slide 19: Question & Answer Period
Question & Answer Period WYALEANT
Bausch Health Companies — Shareholder Meeting (April 2018) on 6ix